ASH Poster Walks

ASH Poster Walk on Beyond Hematology: Clinical and Mechanistic Links between Clonal Hematopoiesis and Non-Hematological Disorders

Clonal hematopoiesis (CH) has emerged as a very common age-associated alteration of hematopoiesis that has manifold associations with inflammatory and cardiovascular disorders. This poster walk will highlight studies from two broad categories:

a) Studies that convincingly demonstrate novel associations between CH and non-hematologic diseases, or offer new insights into the interplay between CH-associated gene mutations, other risk factors, and associated disorders.

b) Abstracts that contribute to our understanding of the underlying biological mechanisms (e.g. inflammatory signaling) linking clonal hematopoiesis to pathologic changes in other organ systems, and/or investigating potential targeted, preventive or therapeutic interventions.

Organizer:

Klaus H. Metzeler, MD
University Hospital Leipzig
Leipzig, Germany

Speakers:

Bhavisha A. Patel, MD
National Institutes of Health
Bethesda, MD
Clonal Hematopoiesis in Vexas Syndrome

Rohan Kodgule, MD,MBBS
Washington University School of Medicine
St Louis, MO
Clonal Myeloid Heterogeneity in Older Autopsy Patients Determined By Multiple Bone Marrow Site Sequencing

Christopher M Arends
Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health
Berlin, Germany
Associations of Clonal Hematopoiesis with Recurrent Vascular Events and Death in Patients with Incident Ischemic Stroke

Fernanda Gutierrez-Rodrigues, PhD
National Institute of Health
Bethesda, MD
Clonal Hematopoiesis in a Broad Age Spectrum of Systemic Vasculitis

Toby Thomas, B.S.
University of Texas Southwestern
Dallas, TX
Clonal Hematopoiesis and Heart Failure with Preserved Ejection Fraction

Ryunosuke Saiki
Graduate School of Medicine, Kyoto University
Kyoto, Japan
Detailed Analysis of the Impact of Clonal Hematopoiesis on the Risk of Severe COVID-19 Infection

ASH Poster Walk on Diversity, Equity, and Inclusion in Hematologic Malignancies and Cellular Therapy

Although outcomes of various hematologic malignancies are improving, disparities continue to impact patients’ access to and outcomes following care. This poster walk will highlight work being done to investigate and address factors which impact the provision of care across malignant hematology for patients from different racial and ethnic backgrounds, those of lower socio-economic status, and other vulnerable groups.

The walk will also feature work being done to make the field more inclusive for patients, institutions, and practitioners. Review of this research will improve the audiences' understanding of disparities in malignant hematology and cellular therapy, which is necessary to identify specific patient groups at risk for compromised care. This information is a pre-requisite to enhance outcomes and care delivery.

Lastly, the walk will serve to connect stakeholders interested in Diversity, Equity, and Inclusion (DEI) in malignant hematology and cellular therapy and will facilitate discussions on the state of DEI research in the field. There will be a discussion on how such efforts can support critically important work to diversify patient populations, mitigate barriers to care, and maximize the equitable provision of optimal care for less or under-privileged groups. 

Organizer:

Warren B Fingrut, MD
Harvard T.H. Chan School of Public Health
Boston, MA

Speakers:

Lama Sawalha, MD
Hashemite University
Amman, Jordan
Analysis of Repeated Roles in Editorial Boards at Oncology-Focused Journals

Adam J. de Smith, PhD
University of Southern California
Los Angeles, CA
Racial and Ethnic Disparities in Childhood Acute Lymphoblastic Leukemia Risk Due to an IKZF1 Noncoding Regulatory Variant

Kara I. Cicero, MD, MPH
Columbia University Medical Center
New York, NY
The Impact of Hispanic Ethnicity on Disease Characteristics in Multiple Myeloma

Erik Wu
Northwestern University Feinberg School of Medicine
Chicago, IL
The Effects of Social Vulnerability on the Prognosis and Outcomes of Hodgkin’s Lymphoma in Adults across the United States

Oluwasegun Akinyemi, MD
Howard University College of Medicine
Macomb, IL
Poor Survival Outcomes Among Patients with Burkitt Lymphoma Are Associated with Socioeconomic Disparities

Reem Karmali, MD,MSc
Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University
Chicago, IL
Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy

ASH Poster Walk on Platelets from Bench to Bedside

Platelets are anucleate cellular fragments that play a central role in hemostasis and thrombosis. Beyond these fundamental functions, platelets also are important in other biological contexts, including cancer progression, immunity, and inflammation.

This poster walk will highlight platelet research across the bench to bedside spectrum. Featured abstracts will highlight studies of platelet biology, clinical/translational studies of disorders of platelet number/function, and studies of platelet transfusion.

Lastly, this poster walk aims to: highlight key knowledge gaps in the field;  highlight methods used to address these knowledge gaps; and encourage early career physicians and scientists to pursue research on platelets and platelet disorders.

Organizer:

Marie Alice Hollenhorst, MD,PhD
Stanford University
Palo Alto, CA

Speakers:

Moritz Stolla, MD
Bloodworks Northwest Research Institute
Seattle, WA
Deletion of 12-Lipoxygenase Improves Platelet Function after Storage and Transfusion in Thrombocytopenic Mice

Huiying Zhi, PhD
Blood Center of Wisconsin
Milwaukee, WI
CD4+ T Cells Are Required for Production of Disease-Causing Antibodies in an Alloantigen-Specific Murine Model of Fetal/Neonatal Alloimmune Thrombocytopenia

Ana Mendoza
Hospital Universitario La Paz
Madrid, AL, Spain
Predictive Value of Platelet Sequestration Studies in Splenectomy Response

Li Guo, MD,PhD
University of Utah
Salt Lake City, UT
Actin Bundling Protein L-Plastin Regulates Megakaryocyte Membrane Rigidity and Platelet Spreading

Yanki Yarman
Thomas Jefferson University
PHILADELPHIA, PA
A Common Variant in GRK5 Reveals a PAR1-Specific Mechanism for Its Regulation of Platelet Function

ASH Poster Walk on The Spectrum of Hemostasis and Thrombosis Research

Non-malignant hematology covers a broad range of topics. This poster walk will highlight basic/translational as well as clinical research abstracts in hemostasis, thrombosis, and platelet disorders to foster discussion across disciplines and to encourage young investigators to pursue this career path.

Trainees/junior faculty will have a unique opportunity to meet with leaders in the field of hemostasis and thrombosis, to get exposure to various topics within non-malignant hematology, and to learn how to interpret the data presented in a poster.

Organizer:

Lisa Baumann Kreuziger, MD
Versiti, Blood Research Institute
Milwaukee, WI

Speakers:

Michelle MH Tan, MSc, BSc
Centre For Haematology, Department of Immunology and Inflammation, Imperial College London
London, United Kingdom
Eltrombopag Causes Cell Cycle Arrest of T Cells through Iron Chelation and Could Modulate the Immune Response in ITP

Camelia Vladescu, MSc
Imperial College Healthcare NHS Trust
London, United Kingdom
Cognitive Impairment in Patients with Immune Thrombocytopenia

Ben J Samelson-Jones, MD, PhD
Children's Hospital of Philadelphia
Philadelphia, PA
Factor VIII Mimetic Rescue of Hemophilia B Causing Factor IX Variants

Nicole Rhoads
Bloodworks Northwest
Seattle, WA
Novel Snake Venom Derived Hemocoagulase Reverses Anticoagulant Effect of Factor Xa Inhibitors, Restores Hemostatic Clot Formation, and Limits Bleeding in Vitro and In Vivo

Pedro E. Alcedo Andrade, MD
National Heart, Lung, and Blood Institute. National Institutes of Health
Bethesda, MD
Thrombotic Manifestations in Patients with Vexas Syndrome

ASH Poster Walk on What's Hot in Sickle Cell Disease Research 2022

Sickle cell disease (SCD) affects 100,000 people living in the US and 250-300,000 births annually worldwide. Despite its frequency, the natural history of SCD and its complications remain poorly understood. Over the past decade, clinical research has led to much progress in disease management, identifying novel therapeutic targets and FDA approval of two new therapies, crizanlizumab and voxelotor, in the fall of 2019. Numerous clinical trials of novel therapeutics and potential curative therapies are ongoing. Large patient registries from the US and Europe have begun to increase our understanding of the disease and its complications.

This poster walk will highlight six abstracts focused on innovative clinical research and promising ongoing trials in SCD.

Organizer:

Elizabeth Sue Klings, MD
Boston University
Boston, MA

Speakers:

Macy L. Early, BA
Johns Hopkins Hospital
Baltimore, MD
Trajectory of Blood Pressure in Pregnant People with Sickle Cell Disease: A Multinational Study

Keli C Coleman
Medical College of Wisconsin and the Children's Research Institute of Children's Wisconsin
Milwaukee, WI
Return Visit Rates after an Emergency Department Treat-and-Release Visit for Children with Sickle Cell Pain Episodes

Rajani P Brandsen, MD
Amsterdam UMC, University of Amsterdam
Amsterdam, Netherlands
Natural History and Rate of Progression of Retinopathy in Patients with Sickle Cell Disease: An 11-Year Retrospective Follow-up Analysis

Kristine Anne Karkoska, MD,MS
University of Cincinnati College of Medicine
Cincinnati, OH
Quantifying Dilated Perivascular Spaces in Children with Sickle Cell Disease

Franklin Njoku, MD, MPH
University of Illinois at Chicago
Chicago, IL
Mortality in Adults with Sickle Cell Disease: Results from the Sickle Cell Disease Implementation Consortium (SCDIC) Registry

Amy Parker Ruhl, MD, MHS
National Institutes of Health
Washington, DC
Pulmonary Function before and after Hematopoietic Cell Transplant in People Living with Sickle Cell Disease